NICE issues final guidance on apixaban for the prevention of VTE after total hip or knee replacement in adults

Homepage

Search the NeLM

Medicines A-Z

Find key information about medicines by name (prototype)

Browse by Categories:

Browse by NeLM area:

NICE issues final guidance on apixaban for the prevention of VTE after total hip or knee replacement in adults

Source: NICE

Date published: 25/01/2012 16:14

Summary

by: Sheetal Ladva

NICE has issued final guidance recommending the use of apixaban for the prevention of venous thromboembolism (VTE) after total hip or knee replacement in adults (TA 245).

About this library entry

Category: 2.8.2 Oral anticoagulants | Clinical guidelines | National Institute of Clinical Excellence (NICE) | Venous Thromboembolism

NeLM area: Evidence > Guidelines

Link (TA 245)

Preview your comment

Add new comment

Comment text:

Comments

There are no comments yet. You could be the first! You must be Logged In to comment.

Printer Friendly Version

Related evidence

2.8.2 Oral anticoagulants

14/02/2012

SMC accepts the use of rivaroxaban (Xarelto™) for the treatment of DVT and the prevention of recurrent DVT and PE following an acute DVT in adults

27/01/2012

A briefing paper on dabigatran and rivaroxaban

12/12/2011

SMC accepts apixaban (Eliquis®) for VTE prevention following orthopaedic surgery

Venous Thromboembolism

14/02/2012

SMC accepts the use of rivaroxaban (Xarelto™) for the treatment of DVT and the prevention of recurrent DVT and PE following an acute DVT in adults

12/12/2011

SMC accepts apixaban (Eliquis®) for VTE prevention following orthopaedic surgery

13/09/2011

SMC accepts dabigatran (Pradaxa®) for prevention of stroke and systemic embolism in AF

Back